juvenile idiopathic arthritis


Tocilizumab in polyarticular juvenile idiopathic arthritis: a cost-utility model for the United Kingdom

Value in Health. 2013;16(7):A564


Chang S, Sawyer L, Dejonckheere F, van Suijlekom-Smit LW, Anink J, Diamantopoulos A



An individual sampling model was developed to reflect the health care system and treatment pathway in the UK


Utility data were derived from a large national database


Costs were calculated from National Health Service reference costs and Personal Social Services perspective


Efficacy inputs were derived from an indirect treatment comparison conducted by Symmetron

Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke


Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review


The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK


Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective